Article Text

Download PDFPDF
Optimal treatment of metastatic pancreatic cancer

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Linked articles: 216135.

  • Funding The authors acknowledge NHS funding to the NIHR Biomedical Research Centre.

  • Competing interests Professor Cunningham has received research funding from Roche, Amgen and Merck Serono. He has an uncompensated consultant/advisory role for Roche, Amgen and Astrazeneca.

  • Provenance and peer review Commissioned; externally peer reviewed.

Linked Articles